# US 7,608,273 B2 · Recombinant lentivirus encoding modified GP 120 signal sequences

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 7,608,273 B2
- Document ID: US7608273B2
- Status: Granted
- Kind: B2
- Application number: 11/107,364
- Filed: 2005-04-15
- Published: 2005-12-08
- Granted: 2009-10-27
- Earliest claimed: 1998-08-12
- Assignees: The University of Western Ontario
- Inventors: Chil-Yong Kang; Yan Li
- Web page: https://patentgrep.com/patent/US7608273B2

## CPC

- A61K 39/21: Retroviridae, e.g. equine infectious anemia virus
- A61K 39/12: Viral antigens
- A61P 31/18: for HIV
- C07K 14/005: from viruses
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61K 2039/5252: {inactivated (killed)}
- A61K 2039/5258: {Virus-like particles}
- A61K 2039/54: {characterised by the route of administration}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/555: {characterised by a specific combination antigen/adjuvant}
- A61K 2039/55561: {CpG containing adjuvants; Oligonucleotide containing adjuvants}
- A61K 2039/57: {characterised by the type of response, e.g. Th1, Th2}
- C07K 2319/02: containing a signal sequence
- C12N 2710/14143: viral genome or elements thereof as genetic vector
- C12N 2710/16061: Methods of inactivation or attenuation
- C12N 2740/16023: Virus like particles [VLP]
- C12N 2740/16122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2740/16134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2740/16234: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2740/16322: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Novel HIV vaccines comprising an avirulent and non-cytolytic recombinant HIVs are provided.

## Claims

### Claim 1

A recombinant lentivirus having a glycoprotein 120 signal sequence, wherein said glycoprotein 120 signal sequence is selected from the group consisting of the polypeptide sequences listed as SEQ ID NO 3-6, or a functional fragment or variant thereof, wherein said functional fragment or variant thereof contains no more than one (1) positively charged amino acid.

### Claim 2 (depends on 1)

The recombinant lentivirus of claim 1, wherein said functional fragment or variant thereof contains one positively charged amino acid.

### Claim 3 (depends on 1)

The recombinant lentivirus of claim 1, wherein said recombinant lentivirus is rendered avirulent by deletion of a sufficient amount of the nef gene.

### Claim 4 (depends on 1)

The recombinant lentivirus of claim 1, which is HIV-1.

### Claim 5 (depends on 1)

The recombinant lentivirus of claim 1, wherein said recombinant lentivirus is rendered avirulent by deletion of a sufficient amount of the nef gene; and said recombinant lentivirus is HIV-1.

### Claim 6

An immunogenic composition comprising a recombinant lentivirus having a glycoprotein 120 signal sequence, wherein said glycoprotein 120 signal sequence is selected from the group consisting of the polypeptide sequences listed as SEQ ID NO 3-6, or a functional fragment or variant thereof, wherein said functional fragment or variant thereof contains no more than one (1) positively charged amino acid.

### Claim 7 (depends on 6)

The immunogenic composition of claim 6, wherein said functional fragment or variant thereof contains one positively charged amino acid.

### Claim 8 (depends on 6)

The immunogenic composition of claim 6, wherein said recombinant lentivirus is rendered avirulent by deletion of a sufficient amount of the nef gene.

### Claim 9 (depends on 6)

The immunogenic composition of claim 6, wherein said recombinant lentivirus is HIV-1.

### Claim 10 (depends on 6)

The immunogenic composition of claim 6, wherein said recombinant lentivirus is rendered avirulent by deletion of a sufficient amount of the nef gene; and said recombinant lentivirus is HIV-1.

### Claim 11 (depends on 6)

The immunogenic composition of claim 6, wherein said functional fragment or variant thereof contains one positively charged amino acid; and said recombinant lentivirus is rendered avirulent by deletion of a sufficient amount of the nef gene.

### Claim 12 (depends on 6)

The immunogenic composition of claim 6, wherein said functional fragment or variant thereof contains one positively charged amino acid; said recombinant lentivirus is rendered avirulent by deletion of a sufficient amount of the nef gene; and said recombinant lentivirus virus is HIV-1.

### Claim 13 (depends on 6)

The immunogenic composition of claim 6, wherein said vaccine further comprises an adjuvant.